
About Zafgen
Zafgen is a publicly listed company based in Cambridge (United States) founded in 2005. Therapeutics for obesity are developed by targeting fat tissue. Zafgen has raised $127.76 million across 6 funding rounds from investors including RA Capital, Atlas Venture and Oxford. Its chief executive, as recorded, is Thomas Hughes. Zafgen offers products and services including Power Shape, Visadore, Acust Oil PRO, Psoryden, and Biotrim Maximum. Its focus areas include Life Sciences, Rare Diseases, Drugs and Metabolic Disorders. Its competitors include Alnylam, Ultragenyx and BioMarin Pharmaceutical; 3 of its 3 listed competitors have raised funding.
Company details
Zafgen was founded in 2005 and is headquartered in Cambridge, United States. The company operates in the biotechnology sector, focusing on the development of therapeutics for obesity treatment. These therapies aim to reduce fat tissue directly, promoting a sustained lean state. The lead candidate, Beloranib, is in phase 3 trials for Prader-Willi syndrome and is evaluated as an alternative to bariatric surgery.
- Headquarters Cambridge, United States
- Stage Public
- SectorsHealthcare
- Website zafgen.com
- Social LinkedIn X
- Total Equity Funding$127.76M (USD)
in 6 rounds
- Latest Funding Round$20M (USD), Debt – Conventional
Apr 2014
- InvestorsRA Capital
& 7 more
Products & Services of Zafgen
Zafgen offers a comprehensive portfolio of products and services, including Power Shape, Visadore, Acust Oil PRO, Psoryden, and Biotrim Maximum.
Capsules aimed at supporting weight loss through dietary aid
Creme for preventing skin aging and maintaining elasticity
Tropfen for managing tinnitus and related ear issues
Creme targeted at treating psoriasis symptoms
Tablets for aiding balanced diet and weight management
Kapseln for diabetes management and health support
Kapseln designed to enhance sexual potency and stamina
Creme for improving sleep and overall well-being
Kapseln for supporting calorie deficit and fat loss
Kapseln for addressing prostate-related health concerns
Funding Insights of Zafgen
Zafgen has successfully raised a total of $127.76M across 6 strategic funding rounds. The most recent funding activity was a Debt β Conventional round of $20 million completed in April 2014. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $127.76M
- Total Rounds 6
- Last Round Debt – Conventional β $20M
- First Round $28M
(Mar 2010)
- Investors Count 8
All 6 funding rounds of Zafgen with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr 2014 | $20M | Debt – Conventional | β | β | |
| Dec 2013 | $45M | Series E | β | β | |
| Dec 2012 | $21.76M | Series D | β | Alta Partners | |
| Aug 2012 | $3M | Debt – Conventional | β | β | β |
| Jul 2011 | $33M | Series C | β | Atlas Venture, Third Rock Ventures | β |
| Mar 2010 | $28M | Series B | β | Third Rock Ventures |
8 investors in total: 8 institutional.
Investors in Zafgen
Zafgen has secured backing from 8 investors, including institutional and venture fund investors. Prominent investors backing the company include RA Capital, Atlas Venture and Oxford.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital firm focused on multiple sectors | brooksidecapital.com | San Francisco, United States | ||
Venture capital firm focused on tech sectors | venrock.com | Palo Alto, United States | ||
Venture capital firm focused on healthcare companies | altapartners.com | Jackson, United States | ||
Venture capital firm investing in life science and biotechnology sectors | 1980 | atlasventure.com | Cambridge, United States | |
Venture capital funding is provided to early-stage life science companies. | thirdrockventures.com | Boston, United States | ||
| oxfordna.org | ||||
Offers customized loans and financing to small and mid-size companies across industries. | 2004 | midcapcredit.com | West Hartford, United States | |
RA Capital is engaged in evidence-based investing in healthcare and life sciences. | 2004 | racap.com | Boston, United States |
Investor details for Zafgen
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Zafgen
10 people are tracked at Zafgen (3 in leadership, 7 in board & advisors).
| Name | Role | Group |
|---|---|---|
Thomas Hughes | CEO | Leadership |
Jeffrey S. Hatfield | CEO | Leadership |
Brian P. Mcveigh | Chief Business Officer | Leadership |
Thomas O. Daniel | Director | Board & advisors |
Peter Barrett | Chairman | Board & advisors |
Wendy Everett | Director | Board & advisors |
Frank E. Thomas | Director | Board & advisors |
Robert J. Perez | Director | Board & advisors |
C. Geoffrey Mcdonough | Director | Board & advisors |
John Lamattina | Director | Board & advisors |
Complete people profiles for Zafgen
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Zafgen
4 dated milestones of Zafgen across 9 years, from founding to its latest funding, stage changes and deals.
- Founded Zafgen is founded.
- Funding First funding round of $28.0M.
- Funding Latest funding round, Debt β Conventional, of $20.0M.
- IPO Lists on the stock exchange (IPO).
Competitors of Zafgen
Zafgen has 3 listed competitors in our database, 3 of them funded. They include Alnylam, Ultragenyx and BioMarin Pharmaceutical.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| alnylam.com | 2002 | Cambridge, United States | $17M | 2,100 | RNA interference-based therapeutics are developed for multiple disorders. | |
| ultragenyx.com | 2010 | Novato, United States | $135.1M | 837 | Therapeutics for rare and ultra-rare metabolic diseases are developed. | |
| biomarin.com | 1997 | San Rafael, United States | $37.5M | 2,124 | Therapeutics for rare genetic diseases are developed by BioMarin Pharmaceutical. |
Detailed competitors of Zafgen
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Zafgen
Websites that share an audience with Zafgen (zafgen.com).
Websites whose visitors overlap most with Zafgen. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| momentapharma.com | 100% | #11,284,544 | View details | ||
| orexigen.com | 94% | View details | |||
| fiercebiotech.com | 89% | 858.3K | #81,022 | View details | |
dddmag.com | dddmag.com | 62% | β | ||
domuk.org | domuk.org | 58% | β | ||
| β’β’β’β’β’β’β’β’β’β’ | β’β’β’β’β’β’.com | β’β’% | β’.β’M | #β’β’β’β’β’ | β |
All 6 similar websites and full traffic analytics for Zafgen
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 6 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Rare Diseases
3 companies that operate in the same segment as Zafgen (Rare Diseases) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Gene therapies for rare diseases including retinal dystrophies are developed. | 2013 | Philadelphia, Pennsylvania, United States | USD 82.8 M | USD 64.73 M | 822 | |
Therapeutics for genetic diseases are developed through targeted interventions. | 2015 | Palo Alto, California, United States | USD 434.2 M | USD 502.08 M | 730 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Zafgen
Complete news archive for Zafgen
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Zafgen
Zafgen was founded in 2005 and raised its 1st funding round 5 years after it was founded.
Zafgen is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Thomas Hughes is the CEO of Zafgen, as recorded in our data.
Zafgen is a funded company, having raised a total of $127.76M across 6 funding rounds to date. The company's 1st funding round was a Series B of $28M, raised on Mar 2010.
Zafgen was founded in 2005 and is headquartered in Cambridge, United States. The company operates in the biotechnology sector, focusing on the development of therapeutics for obesity treatment. These therapies aim to reduce fat tissue directly, promoting a sustained lean state. The lead candidate, Beloranib, is in phase 3 trials for Prader-Willi syndrome and is evaluated as an alternative to bariatric surgery.
Zafgen's top competitors include Alnylam, BioMarin Pharmaceutical and Ultragenyx.
Zafgen offers Power Shape, Visadore, Acust Oil PRO, Psoryden, and 6 more products and services.
Zafgen has 8 investors. Key investors include RA Capital, Atlas Venture, Oxford, Midcapcredit, and Brookside Capital.
